Amneal Pharmaceuticals (NASDAQ:AMRX) Issues FY 2025 Earnings Guidance

Amneal Pharmaceuticals (NASDAQ:AMRX) updated its FY 2025 earnings guidance on Friday. The company provided EPS guidance of 0.650-0.700 for the period, compared to the consensus EPS estimate of 0.710. The company issued revenue guidance of $3.0 billion-$3.1 billion, compared to the consensus revenue estimate of $2.9 billion.

Amneal Pharmaceuticals Trading Up 2.1 %

NASDAQ:AMRX traded up $0.18 during trading hours on Friday, hitting $8.56. 1,210,842 shares of the stock traded hands, compared to its average volume of 1,275,363. The firm has a 50 day moving average price of $8.08 and a 200 day moving average price of $8.31. Amneal Pharmaceuticals has a fifty-two week low of $5.01 and a fifty-two week high of $9.48. The firm has a market cap of $2.65 billion, a price-to-earnings ratio of -12.58 and a beta of 1.10.

Analyst Upgrades and Downgrades

AMRX has been the topic of several recent analyst reports. JPMorgan Chase & Co. raised shares of Amneal Pharmaceuticals from a “neutral” rating to an “overweight” rating and boosted their target price for the company from $9.00 to $12.00 in a research note on Monday. Piper Sandler boosted their target price on shares of Amneal Pharmaceuticals from $9.00 to $11.00 and gave the company an “overweight” rating in a research note on Monday, November 11th. Finally, StockNews.com downgraded shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, December 19th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $10.60.

Insider Buying and Selling at Amneal Pharmaceuticals

In related news, Director Gautam Patel sold 62,590 shares of the stock in a transaction dated Wednesday, January 8th. The shares were sold at an average price of $8.01, for a total value of $501,345.90. Following the completion of the sale, the director now owns 1,968,886 shares in the company, valued at approximately $15,770,776.86. This trade represents a 3.08 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold 160,000 shares of company stock worth $1,292,000 over the last ninety days. Company insiders own 26.56% of the company’s stock.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.